Biorestorative Therapies, INC 8-K filings

BioRestorative Therapies, Inc. has immediately suspended all orders and shipments of its biocosmeceutical product lines, ExoCR and BioX, pending a business review and regulatory assessment.

Biorestorative Therapies announces significant executive departures and board appointments, alongside amendments to executive employment agreements.

BioRestorative Therapies, Inc. has entered into a new three-year employment agreement with its Vice President of Research and Development, Francisco Silva.

BioRestorative Therapies, Inc. entered into a $1 million revolving loan agreement with Bowery Group LLC, resulting in the resignation of three directors and the appointment of three lender-designated board members.

BioRestorative Therapies stockholders approved an increase in authorized common stock to 1.5 billion shares and formalized executive employment agreements.

BioRestorative Therapies has finalized discretionary cash bonuses and total compensation packages for its top executive leadership team for the 2025 fiscal year.

BioRestorative Therapies, Inc. has published an updated corporate presentation for use in upcoming investor meetings and conferences.

BioRestorative Therapies, Inc. announced its financial results for the third quarter ended September 30, 2025, via a press release.

BioRestorative Therapies, Inc. completed a registered direct offering and concurrent private placement of warrants, raising $1.085 million to advance its cell therapy programs.

BioRestorative Therapies, Inc. stockholders approved the election of Class II directors, an expanded stock incentive plan, auditor ratification, and executive compensation at their Annual Meeting.

BioRestorative Therapies, Inc. announced the availability of an updated corporate presentation for investor meetings and conferences.

BioRestorative Therapies, Inc. filed an 8-K to announce its second quarter 2025 financial results and business update.

BioRestorative Therapies, Inc. announced promising preliminary blinded data from its ongoing Phase 2 clinical trial of BRTX-100 for chronic lumbar disc disease, demonstrating significant improvements in pain and function that exceed FDA thresholds.

BioRestorative Therapies, Inc. released its financial results for the first quarter ended March 31, 2025, along with a business update, as detailed in a press release issued on May 14, 2025.

BioRestorative Therapies, Inc. announces the resignation of Marcum LLP as its independent registered public accounting firm and the engagement of CBIZ CPAs P.C. effective April 16, 2025.

BioRestorative Therapies, Inc. will release its financial results for the year ended December 31, 2024, after market close on March 27, 2025, followed by a management-hosted conference call.

BioRestorative Therapies' VP of Research and Development presented at the Orthopaedic Research Society (ORS) 2025 Annual Meeting in Phoenix, Arizona on February 8, 2025.

BioRestorative Therapies reported positive preliminary data from its Phase 2 clinical trial for BRTX-100 and announced its third quarter 2024 financial results, showing a reduction in operating losses.

BioRestorative Therapies will present additional data from its Phase 2 clinical trial of BRTX-100 and its third quarter 2024 financial results on November 13, 2024.

BioRestorative Therapies has entered into an agreement to potentially sell up to $3.6 million of its common stock through an at-the-market offering.

BioRestorative Therapies held its Annual Meeting of Stockholders on September 19, 2024, where a Class I director was elected, an amendment to the 2021 Stock Incentive Plan was approved, and the selection of Marcum LLP as the independent auditor was ratified.

BioRestorative Therapies released its financial results for the second quarter ended June 30, 2024, along with a business update.

BioRestorative Therapies will release its second quarter 2024 financial results on August 13, 2024, followed by a conference call to discuss the results and provide a business update.

BioRestorative Therapies received a notice from Nasdaq for failing to file its quarterly report, putting its listing status at risk.

BioRestorative Therapies will restate its financial statements from 2022 and 2023 due to a misapplication of accounting standards related to warrants.

BioRestorative Therapies will participate in the 36th Annual ROTH Conference, with CEO Lance Alstodt scheduled for a fireside chat.

BioRestorative Therapies has raised approximately $8.1 million by incentivizing existing warrant holders to exercise their warrants at a reduced price, while also issuing new warrants.

BioRestorative Therapies released preliminary data from its Phase 2 clinical trial of BRTX-100, showing positive trends in pain and function for patients with chronic lumbar disc disease.

BioRestorative Therapies will present preliminary 26-week blinded data from its Phase 2 clinical trial of BRTX-100 for chronic lumbar disc disease at the Orthopaedic Research Society 2024 Annual Meeting.